Congo Ebola Outbreak Surpasses 11,000 Cases
An Ebola outbreak in the Democratic Republic of the Congo has become the second-deadliest on record, with over 11,000 confirmed cases and 5,387 deaths, driven by a vaccine-resistant virus strain and severe security challenges.
The Democratic Republic of the Congo's Ebola outbreak has surpassed 11,000 confirmed cases with 5,387 deaths, making it the second-deadliest outbreak in history. Health ministry data released on November 10 confirmed 11,042 cases and a case fatality ratio of about 48.8 percent.
The outbreak was declared on May 15 and designated a public health emergency of international concern by the World Health Organization two days later. It is the largest and deadliest in Congo's history. The Bundibugyo virus strain responsible has no licensed vaccine and no approved specific treatment. The existing Ervebo vaccine targets a different strain.
Containment efforts have been severely hampered by armed conflict, a health system crisis, and community mistrust. Health facilities and workers have been targeted in attacks. Violence in major hotspots like Ituri province, where 28 of 36 health zones are affected, has restricted access. Transmission is slowing in some areas but new hotspots are emerging due to insecurity and population displacement.
| Metric | Figure |
|---|---|
| Confirmed Cases | 11,042 |
| Deaths | 5,387 |
| Case Fatality Ratio | 48.8% |
| Provinces Affected | 8 out of 26 |
| Health Zones Affected | 67 |
The outbreak has already had at least three times the number of cases and deaths in the same timeframe as the 2014-2016 West African epidemic, which remains the largest with over 28,600 infections and 11,000 deaths. The virus has spread to multiple African countries including Uganda, Kenya, and Nigeria.
WHO Approves New Vaccine Trials
This month, the WHO approved clinical trials for two new vaccines targeting the Bundibugyo strain. Results are expected in early 2027. Meanwhile, Doctors Without Borders has requested the WHO lift restrictions that limit the use of the Ervebo vaccine to research purposes in this outbreak, arguing for its potential use despite the strain mismatch.
AMA Addresses Systemic Health Challenges
The American Medical Association has adopted several new policies addressing systemic issues in healthcare. It now designates moral injury as a significant threat to physicians and medical students. The association also strengthened its opposition to payer downcoding practices and voiced support for medication deprescribing. Also, it urged the federal government to rescind relaxed rules on unapproved peptide compounding.
In related policy movements, Democrats are pressing drug manufacturers to release complete, unredacted copies of their drug pricing deals with the previous administration. Californians approved $8.4 billion in state bonds for immunology research.
Concurrent Public Health Developments
Other significant health developments are unfolding alongside the Ebola crisis. The United States has recorded 5,100 measles cases this year, generating an estimated $83 million in economic costs. In food safety, Family Farmstead Dairy expanded its recall to include all cheddar cheese products due to potential Listeria contamination.
New medical research includes a modeling study suggesting breast cancer chemotherapy may accelerate biological aging and raise mortality risk. The American Society of Addiction Medicine released its first clinical guidance for managing medetomidine intoxication and withdrawal. The administration also announced $10 billion in awards for the second year of the Rural Health Transformation Program.
The critical need for new interventions against Ebola is showed by the timeline for vaccine trials. Health authorities are now waiting for results, which are not expected until early 2027.
